Acute pharmacologic blockade of dyskinesias in Parkinson's disease
Identifieur interne : 005715 ( Main/Curation ); précédent : 005714; suivant : 005716Acute pharmacologic blockade of dyskinesias in Parkinson's disease
Auteurs : Pierre J. Blanchet [États-Unis] ; Leo Verhagen Metman [États-Unis] ; M. Maral Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1996-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Antiparkinson agent, Case study, Chemotherapy, Dextrorphan (administration & dosage), Dextrorphan (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Excitatory Amino Acid Antagonists (administration & dosage), Excitatory Amino Acid Antagonists (therapeutic use), Human, Humans, Levodopa, Levodopa (therapeutic use), Middle Aged, Movement Disorders (complications), Movement Disorders (drug therapy), Parkinson Disease (complications), Parkinson disease, Placebos, Secondary effect, Severity of Illness Index, Toxicity, Treatment.
- MESH :
- chemical , administration & dosage : Dextrorphan, Excitatory Amino Acid Antagonists.
- chemical , therapeutic use : Dextrorphan, Excitatory Amino Acid Antagonists, Levodopa.
- complications : Movement Disorders, Parkinson Disease.
- drug therapy : Movement Disorders.
- Double-Blind Method, Drug Therapy, Combination, Humans, Middle Aged, Placebos, Severity of Illness Index.
Url:
DOI: 10.1002/mds.870110516
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003F17
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :003F17
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003C17
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004777
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004777
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004882
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004C05
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :004C05
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004C05
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :008821
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003340
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :003484
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003416
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :008948
Links to Exploration step
ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
</author>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1002/mds.870110516</idno>
<idno type="url">https://api.istex.fr/document/1AE004D10FF1E0AC84B081B1E59D8C0E2230B537/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003F17</idno>
<idno type="wicri:Area/Istex/Curation">003F17</idno>
<idno type="wicri:Area/Istex/Checkpoint">003C17</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8866502</idno>
<idno type="wicri:Area/PubMed/Corpus">004777</idno>
<idno type="wicri:Area/PubMed/Curation">004777</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004882</idno>
<idno type="wicri:Area/Ncbi/Merge">004C05</idno>
<idno type="wicri:Area/Ncbi/Curation">004C05</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C05</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:Area/Main/Merge">008821</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:96-0423275</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003340</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003484</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003416</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:Area/Main/Merge">008948</idno>
<idno type="wicri:Area/Main/Curation">005715</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1996-09">1996-09</date>
<biblScope unit="vol">11</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="580">580</biblScope>
<biblScope unit="page" to="581">581</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1AE004D10FF1E0AC84B081B1E59D8C0E2230B537</idno>
<idno type="DOI">10.1002/mds.870110516</idno>
<idno type="ArticleID">MDS870110516</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dextrorphan (administration & dosage)</term>
<term>Dextrorphan (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia</term>
<term>Excitatory Amino Acid Antagonists (administration & dosage)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Movement Disorders (complications)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Placebos</term>
<term>Secondary effect</term>
<term>Severity of Illness Index</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dextrorphan</term>
<term>Excitatory Amino Acid Antagonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dextrorphan</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Dyskinésie</term>
<term>Effet secondaire</term>
<term>Etude cas</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<double idat="0885-3185:1996:Blanchet P:acute:pharmacologic:blockade"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0423275</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0423275 INIST</idno>
<idno type="RBID">Pascal:96-0423275</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003340</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003484</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003416</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:Area/Main/Merge">008948</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Metman, L V" sort="Metman, L V" uniqKey="Metman L" first="L. V." last="Metman">L. V. Metman</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Secondary effect</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Effet secondaire</term>
<term>Toxicité</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude cas</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
</author>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1002/mds.870110516</idno>
<idno type="url">https://api.istex.fr/document/1AE004D10FF1E0AC84B081B1E59D8C0E2230B537/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003F17</idno>
<idno type="wicri:Area/Istex/Curation">003F17</idno>
<idno type="wicri:Area/Istex/Checkpoint">003C17</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8866502</idno>
<idno type="wicri:Area/PubMed/Corpus">004777</idno>
<idno type="wicri:Area/PubMed/Curation">004777</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004882</idno>
<idno type="wicri:Area/Ncbi/Merge">004C05</idno>
<idno type="wicri:Area/Ncbi/Curation">004C05</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C05</idno>
<idno type="wicri:doubleKey">0885-3185:1996:Blanchet P:acute:pharmacologic:blockade</idno>
<idno type="wicri:Area/Main/Merge">008821</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Acute pharmacologic blockade of dyskinesias in Parkinson's disease</title>
<author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch National Institute of Neurological Disorders and Stroke Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1996-09">1996-09</date>
<biblScope unit="vol">11</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="580">580</biblScope>
<biblScope unit="page" to="581">581</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1AE004D10FF1E0AC84B081B1E59D8C0E2230B537</idno>
<idno type="DOI">10.1002/mds.870110516</idno>
<idno type="ArticleID">MDS870110516</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dextrorphan (administration & dosage)</term>
<term>Dextrorphan (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Excitatory Amino Acid Antagonists (administration & dosage)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Movement Disorders (complications)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Parkinson Disease (complications)</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dextrorphan</term>
<term>Excitatory Amino Acid Antagonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dextrorphan</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005715 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 005715 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:1AE004D10FF1E0AC84B081B1E59D8C0E2230B537 |texte= Acute pharmacologic blockade of dyskinesias in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |